retatrutide type 2 diabetes phase 2 results 2024 2025 Lilly's triple agonist achieves 16.8% weight loss in 3 trial Retatrutide study sees significant weight

Retatrutide (formerly LY3437943) is a once-weekly injectable drug developed by Eli Lilly

N khng ch tn ph ln da, y nhanh lo ha m cn nh hng xu n ton b cc chc nng trong c th

Talk to a doctor or another healthcare provider before taking any of the following supplements

This makes injection a better choice than depending on the digestive tract for absorption

La dosis se aumenta gradualmente en incrementos de 2.5 mg cada 4 semanas segn la respuesta clnica y tolerabilidad, hasta alcanzar dosis de mantenimiento de 5-15 mg semanales

GLP-1s are also recommended for blood sugar control in those who have a goal of weight loss in addition to managing their diabetes